A systematic review of biomarkers for disease progression in Parkinson's disease

BMC Neurology

Volumn 13, Issue , 2013, Pages

  McGhee, David J M ^a   Royle, Pamela L ^b   Thompson, Paul A ^c   Wright, David E ^c   Zajicek, John P ^d   Counsell, Carl E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Biomarkers; Clinical trials; Disease progression; Neuroprotective agents; Parkinson disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BIOLOGICAL MARKER;

ARTICLE; BLOOD; CEREBROSPINAL FLUID; CLINICAL STUDY; CROSS SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; ELECTROPHYSIOLOGY; EMBASE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MEDLINE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PLASMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUESTIONNAIRE; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SERUM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; STATISTICS; STUDY DESIGN; SYSTEMATIC REVIEW; ULTRASOUND; URINE;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 84877070118     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-35     Document Type: Article

References (31)

1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003, 18(1):19-31. 10.1002/mds.10305, 12518297.
2. Clarke CE. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?. Mov Disord 2004, 19(5):491-498. 10.1002/mds.20057, 15133811.
3. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009, 72(Suppl 7):S51-S58.
4. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?. Mov Disord 2008, 23(6):784-789. 10.1002/mds.21918, 18175348.
5. Temple RJ. A regulatory authority's opinion about surrogate endpoints. Clinical Measurement in Drug Evaluation 1995, New York: J. Wiley, Nimmo WS, Tucker GT.
6. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95. Biomarkers Definitions Working Group.
7. Consensus report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease": The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998, 19(2):109-116. Consensus report of the Working Group on.
8. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003, 184(Suppl 1):S68-S79.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55(3):181-184. 10.1136/jnnp.55.3.181, 1014720, 1564476.
10. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56(1):33-39. 10.1001/archneur.56.1.33, 9923759.
11. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992, 32(Suppl 1):S125-S127.
12. Weiner WJ, Lang AE. Parkinson's disease. Movement Disorders, A comprehensive survey 1989, 23-115. Mount Kisco, New York: Futura Publishing, Weiner WJ, Lang AE.
13. Fahn S, Eton RL. UPDRS Development Committee: The Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease Volume 2 1987, 153-163. Florham Park, New Jersey: Macmillan Healthcare Information, Fahn S, Marsden CD, Goldstein M, Calne DB.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12(3):189-198. 10.1016/0022-3956(75)90026-6, 1202204.
15. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986, 149:698-709. 10.1192/bjp.149.6.698, 3790869.
16. Huber SJ, Paulson GW, Shuttleworth EC. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51(6):855-858. 10.1136/jnnp.51.6.855, 1033160, 3404193.
17. Yamamoto M. Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background. J Neurol 2001, 248(Suppl 3):III5-III11.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23(36):9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
19. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004, 19(9):1020-1028. 10.1002/mds.20213, 15372591.
20. Firbank MJ, Molloy S, McKeith IG, Burn DJ, O'Brien JT. Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson's disease over one year. J Neurol Neurosurg Psychiatry 2005, 76(10):1448-1451. 10.1136/jnnp.2004.058685, 1739344, 16170094.
21. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130(7):1834-1846. 10.1093/brain/awm086, 17470495.
22. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 2001, 108(8-9):1011-1019.
23. Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287(13):1653-1661. 10.1001/jama.287.13.1653, 11926889, Parkinson Study Group.
24. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007, 6(12):1094-1105. 10.1016/S1474-4422(07)70290-9, 18031706.
25. Taylor KS, Counsell CE, Harris CE, Gordon JC, Smith WC. Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 2006, 21(7):976-982. 10.1002/mds.20866, 16570298.
26. Bewick V, Cheek L, Ball J. Statistics review 7: Correlation and regression. Crit Care 2003, 7:451-459. 10.1186/cc2401, 374386, 14624685.
27. Altman DG. Relation between two continuous variables. Practical Statistics for Medical Research 1993, 277-324. London: Chapman & Hall.
28. Brown H, Prescott R. Repeated measures data. Applied mixed models in medicine 2006, 215-270. Chichester: J. Wiley, 2.
29. Parkinson's Progressive Markers Initative (PPMI) http://ppmi-info.org/.
30. Parkinson's Disease Biomarkers Program (PDBP) http://pdbp.ninds.nih.gov/.
31. Alzhiemer's Disease Neuroimaging Initative (ADNI) http://adni-info.org/.